Sotatercept in Pulmonary Arterial Hypertension: Central, Hematologic, and Peripheral Mechanisms of Benefit Sotatercept improves small airway disease and hyperinflation in patients with pulmonary hypertension
Catheter-directed thrombolysis (CDL) and mechanical thrombectomy (MT) are increasingly used for intermediate–high–risk pulmonary embolism (PE), yet comparative long-term outcomes remain uncertain. We aimed to compare the effectiveness and safety of CDL versus MT in real-world clinical practice.
Pregnancy poses substantial risks for women with Pulmonary Arterial Hypertension (PAH). This study aimed to evaluate maternal and neonatal outcomes in a contemporary PAH cohort under modern management, specifically investigating whether vasoreactive status warrants distinct clinical recommendations.
Sotatercept has recently expanded treatment options for pulmonary arterial hypertension (PAH), but its mental health and quality-of-life impact is not well characterized. We assessed psychiatric diagnoses and patient-reported outcomes in PAH patients treated with sotatercept within the clinical trial program.
Pulmonary arterial hypertension (PAH) involves complex vascular remodeling. The hypoxia-inducible factor (HIF) pathway is a central oxygen-sensing mechanism, but its circulating profile in PAH is poorly defined. This case-control study included 71 patients with PAH and 93 age- and sex-matched healthy controls.
Pulmonary arterial hypertension (PAH) is associated with significant symptoms and impaired health-related quality of life (HRQOL) and survival. Specialty palliative care (SPC), an intervention delivered by a multidisciplinary team, is focused on improving HRQOL.
Pulmonary arterial hypertension (PAH) carries a high risk of maternal morbidity and mortality in pregnancy, and current guidelines advise against conception. For women with PAH who wish to have genetically related children, in vitro fertilisation (IVF) combined with gestational surrogacy presents a viable and increasingly safe alternative.
Pulmonary arterial hypertension (PAH) is a life-threatening disease of the pulmonary arteries. Progressively increasing pulmonary artery pressure may lead to fatal failure of the right ventricle, necessitating aggressive drug treatment. Sotatercept, a novel drug for PAH-targeted therapy, shows promising results in clinical trials.
